Japan Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the Japan cardiovascular devices market size was valued at USD 3.16 billion in 2025 and estimated to grow from USD 3.34 billion in 2026 to reach USD 4.41 billion by 2031, at a CAGR of 5.73% during the forecast period (2026-2031).

This report is Segmented by Device Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, Heart Failure & Cardiomyopathy, and More), and End User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD).

Japan Cardiovascular Devices Market Trends and Insights

Ageing population intensifies cardiac disease burden

Nearly 29.1% of Japanese citizens are now above 65 years, the highest proportion globally. That demographic trend correlates with rising prevalence of atrial fibrillation, heart failure, and aortic stenosis, boosting long-term demand for stents, valves, pacemakers, and diagnostic monitors. Sudden cardiac death already claims more than 80,000 Japanese lives each year. Cohort data involving 3.5 million working-age adults shows a 96% jump in adverse cardiovascular outcomes among individuals with significant ECG abnormalities. Those statistics strengthen government resolve to fund preventive screening programs and device-based therapies nationwide.

Nationwide reimbursement codes for TAVI & PCI

Since 2021 Japan's Ministry of Health, Labour and Welfare (MHLW) has consistently upgraded reimbursement schedules for transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI). Cost-effectiveness models indicate TAVI is economically dominant for intermediate-risk patients and cost-effective for low-risk cohorts, with incremental ratios well below the ¥5 million per quality-adjusted life-year benchmark. The broadened codes enlarge the eligible patient pool and incentivize hospitals to invest in imaging, fractional-flow reserve systems, and next-gen stent platforms.

Price revision policies under NHI reduce device ASPs

Japan's biennial NHI price review slashed balloon catheter reimbursement from JPY 300,000 to JPY 32,000 and drug-eluting stents from JPY 421,000 to JPY 136,000 between 2022 and 2024. The Central Social Insurance Medical Council forecasts an additional 4% cut in 2025 after detecting a 6% divergence between invoice prices and real-world purchasing costs. Continuous price erosion forces manufacturers to launch value-added upgrades just to maintain revenue trajectories.

Other drivers and restraints analyzed in the detailed report include:

1. High penetration of ECG screening in community clinics
2. Preference for minimally invasive valve repairs
3. Talent shortage in electrophysiology subspecialty

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic & surgical devices generated 75.72% of 2025 revenue. Coronary stents, rhythm-management implants, and heart valves lead the pack, even though biennial price cuts challenge legacy platforms. Emerging trends include drug-coated balloons for complex lesions and polymer-free stents aimed at speeding endothelial healing.

Diagnostic & monitoring devices presently account for 24.28% of value but will outpace therapeutics with a 6.72% CAGR. Remote cardiac monitors, AI-enhanced ECG analyzers, and home-based hemodynamic sensors headline growth. The 2025 relaxation of direct-to-consumer advertising rules has already boosted retail sales of wearable ECG patches. Community clinics connect those devices to cloud platforms, allowing cardiologists in urban centers to interpret rural patient data in real time.

Complete Report Scope:

• By Device Type
  • Diagnostics Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Application
  • Coronary Artery Disease
  • Arrhythmia & Conduction Disorders
  • Heart Failure & Cardiomyopathy
  • Structural & Congenital Heart Defects
  • Peripheral Vascular Disease
• By End User
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

List of Companies Covered in this Report:

1. Terumo
2. Abbott Laboratories
3. Medtronic
4. Boston Scientific
5. Nihon Kohden
6. Nipro
7. Edward Lifesciences
8. Johnson & Johnson (Biosense Webster & Cordis)
9. Koninklijke Philips
10. Siemens Healthineers
11. Fukuda Denshi Co., Ltd.
12. Asahi Intecc Co., Ltd.
13. Shockwave Medical Inc.
14. Canon
15. Maquet Cardiopulmonary GmbH
16. LivaNova
17. W. L. Gore & Associates
18. Merit Medical Systems
19. Zoll Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support